"The Indian market is only 0.25% of the global plasma products market. Plasma fractionators in India face a major challenge with low price imports. Economic pressures mean pressures on technology to deliver multiple products from high yielding processes. The country must support more than one fractionation plant to even begin to meet the needs of the Indian population. The challenges in relation to current healthcare development and the immensity of the issues in a country of 1.1 billion people are discussed in the HIV context are discussed. India is a country of major opportunity and boasts advantages in science and education, biopharmaceutical R & D, productivity and a low age population."
NSP PrIME just arrives at right time at right market, all the best for the cooperation with ABS in India!
MEM Price at posting:
7.5¢ Sentiment: LT Buy Disclosure: Held
